Connect with us

Hi, what are you looking for?


The U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for Amicus Therapeutics’ (NASDAQ: FOLD) two components of AT-GAA submission, Biologics...


SINGAPORE, May 10, 2022 (GLOBE NEWSWIRE) — Proteona Pte. Ltd., a subsidiary of Singleron Biotechnologies, and a leader in single-cell multi-omics analysis, today announced...

More Posts